Pharmsynthez Statistics

Total Valuation

Pharmsynthez has a market cap or net worth of RUB 1.36 billion. The enterprise value is 2.05 billion.

Market Cap	1.36B
Enterprise Value	2.05B

Important Dates

The next estimated earnings date is Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharmsynthez has 301.01 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	301.01M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+2.56%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.92
PB Ratio	2.13
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.75
EV / Sales	5.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.65

Financial Position

The company has a current ratio of 0.54, with a Debt / Equity ratio of 1.20.

Current Ratio	0.54
Quick Ratio	0.45
Debt / Equity	1.20
Debt / EBITDA	n/a
Debt / FCF	-2.10
Interest Coverage	-2.76

Financial Efficiency

Return on equity (ROE) is -61.90% and return on invested capital (ROIC) is -6.08%.

Return on Equity (ROE)	-61.90%
Return on Assets (ROA)	-4.65%
Return on Capital (ROIC)	-6.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.22
Inventory Turnover	4.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-24.60%
50-Day Moving Average	3.92
200-Day Moving Average	5.11
Relative Strength Index (RSI)	63.97
Average Volume (20 Days)	9,839,310

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmsynthez had revenue of RUB 344.17 million and -303.66 million in losses. Loss per share was -1.02.

Revenue	344.17M
Gross Profit	74.05M
Operating Income	-114.14M
Pretax Income	-305.94M
Net Income	-303.66M
EBITDA	-97.72M
EBIT	-114.14M
Loss Per Share	-1.02

Full Income Statement

Balance Sheet

The company has 257.06 million in cash and 761.02 million in debt, giving a net cash position of -503.96 million or -1.67 per share.

Cash & Cash Equivalents	257.06M
Total Debt	761.02M
Net Cash	-503.96M
Net Cash Per Share	-1.67
Equity (Book Value)	636.35M
Book Value Per Share	2.11
Working Capital	-475.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -325.89 million and capital expenditures -36.69 million, giving a free cash flow of -362.58 million.

Operating Cash Flow	-325.89M
Capital Expenditures	-36.69M
Free Cash Flow	-362.58M
FCF Per Share	-1.20

Full Cash Flow Statement

Margins

Gross margin is 21.51%, with operating and profit margins of -33.16% and -88.23%.

Gross Margin	21.51%
Operating Margin	-33.16%
Pretax Margin	-88.89%
Profit Margin	-88.23%
EBITDA Margin	-28.39%
EBIT Margin	-33.16%
FCF Margin	-105.35%

Dividends & Yields

Pharmsynthez does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.60%
Shareholder Yield	1.60%
Earnings Yield	-22.54%
FCF Yield	-26.74%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pharmsynthez has an Altman Z-Score of -3.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.42
Piotroski F-Score	n/a